Rare Tumor News
Recent news about the MyPART program and other advances in the study of rare tumors.
The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis type 1 (NF1) and tumors called plexiform neurofibromas. Read the full blog post published by NCI Staff on April 14, 2020.
MyPART, Center for Cancer Research, and the Chordoma Foundation collaborated to host the first childhood, teen, and young adult Chordoma Clinic at NIH from April 16th to 18th, 2019. The clinic aimed to share knowledge and to collect data for research on chordoma affecting young people.
MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients
Selumetinib, a treatment for Neurofibromatosis Type 1, was given a breakthrough designation by the FDA to treat pediatric patients. (CCR News Headlines - April 12, 2019)